Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

"New Class" is more likely the new "Standard of Care"

March 27, 2008

Analysis of:Enbrel, Perception and Remicade Fostering a New Class of Drugs | www.pharmalive.com

A delay in instituting aggressive antirheumatic medications such as the biologic response modifiers has long term implications in irreversible joint damage. Cost considerations (particularly with the looming potential of "universal healthcare" under a new administrations promises) with exponentially increased exposure and utilization to these drugs could be staggering. These drugs are not only effective, but are proving to have a very favorable safety record.

New Osteoporosis Drug Reduces Mortality after Hip Fracture without increase in Cardiovascular Events

October 5, 2007

Analysis of:U.S. reviews osteoporosis drugs' effect on heart | www.reuters.com

In a recent hip fracture intervention trial released on the New England Journal of Medicine website by Lyles, et al on Sept 17,2007 (not scheduled to be released in print until Nov 1 2007) Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture A placebo controlled study with over 2000 subjects there was no increase in atrial fibrillation or other cardiovascular events in the treated group compared to the placebo group. This was an extension of the HORIZON data published in the NEJM earlier this year.

Page : 11 to 2 of 2

Subscribe to Updates

By RSS